Wolfgang Miesbach: ISTH 2026 Explores the Next Generation of APS Diagnostics
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on Linkedin:
“A pioneer in APS testing, Prof. Pier Luigi Meroni delivered a powerful message at ISTH 2026 in Paris yesterday: what do we really target with our aPL assays?
His update on harmonizing ELISA and non‑ELISA antiphospholipid antibody tests with new commutable reference material for anti‑β2GPI and aCL IgG showed that standardization of units is possible—but that variability from assay design and antibody heterogeneity remains.
For me, the key takeaway was a clear shift from ‘any aPL positive’ towards biologically meaningful β2GPI‑dependent specificities and domain reactivity, which should drive future APS risk stratification, classification, and guidelines.
But how ready are our routine laboratories to embrace this more targeted, domain‑focused approach to APS testing?”
Other posts featuring Wolfgang Miesbach on Hemostasis Today.
-
Aug 31, 2026, 05:35Does LDL Cholesterol Influence VTE Risk? – Ordo Fraterna Fibonacci
-
Aug 31, 2026, 05:19Tania Ahuja: Apixaban in Abdominal Transplant Patients
-
Aug 31, 2026, 04:28Reza Hafidz Irawan։ Automated Antibody Titration With Erytra Eflexis
-
Aug 31, 2026, 04:17Safa Chenganath: Stenosis vs Thrombosis – Hemodialysis Vascular Access
-
Aug 30, 2026, 17:13J. Meireles-Brandao: Hypertension, Inflammation and Lipoprotein Disease
-
Aug 30, 2026, 17:10Hugh Nguyen: Leading the New Era of Blood Services Across Asia Pacific
-
Aug 30, 2026, 17:09Transforming Childhood Through Access to Hemophilia Treatment – World Federation of Hemophilia
-
Aug 30, 2026, 17:07Raj Bharath: Connecting Clinicians and Researchers to Advance Transfusion Medicine
-
Aug 30, 2026, 17:04Rana Al Hrout: Free FRCPath Haematology Part 1 Exam Preparation Session